Sangamo Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and a Favorable Safety Profile

Uncategorized

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

Conference call and webcast scheduled for Tuesday, August 8 , 4:30 p.m. Eastern Time . BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 8, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2023 financial results.